COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
34 hedge funds and large institutions have $1.74M invested in COSCIENS Biopharma Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.
107% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $648K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
10% more funds holding
Funds holding: 31 → 34 (+3)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
24% less capital invested
Capital invested by funds: $2.29M → $1.74M (-$547K)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
+$212K |
| 2 |
Goldman Sachs
New York
|
+$159K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$117K |
| 4 |
Renaissance Technologies
New York
|
+$106K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$337K |
| 2 |
Millennium Management
New York
|
-$155K |
| 3 |
Jane Street
New York
|
-$98K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58.2K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$39K |
CSCI Hedge Fund Activity: Q2 2021 in Review
34 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q2 2021, worth a combined $1.74M — down 24% from $2.29M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CSCI positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 9 trimmed.
The largest buyer was Natixis, opening a new position worth an estimated $212K. The largest seller was Sabby Management, cutting an estimated $337K.
- 34 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q2 2021, up from 31 in Q1 2021.
- Funds reported $1.74M of COSCIENS Biopharma Inc. Common Stock stock for Q2 2021, down 24% quarter-over-quarter.
- 8 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q2 2021 and 5 closed out, a net change of +3 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q2 2021 was Natixis, an estimated $212K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q2 2021 was Sabby Management, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2021.